ESSA Pharma (EPIX) Competitors $1.71 +0.01 (+0.82%) As of 10:18 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPIX vs. AARD, OLMA, AVTE, OCGN, GLUE, AVIR, PRME, TKNO, RCKT, and LFCRShould you be buying ESSA Pharma stock or one of its competitors? The main competitors of ESSA Pharma include Aardvark Therapeutics (AARD), Olema Pharmaceuticals (OLMA), Aerovate Therapeutics (AVTE), Ocugen (OCGN), Monte Rosa Therapeutics (GLUE), Atea Pharmaceuticals (AVIR), Prime Medicine (PRME), Alpha Teknova (TKNO), Rocket Pharmaceuticals (RCKT), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical products" industry. ESSA Pharma vs. Its Competitors Aardvark Therapeutics Olema Pharmaceuticals Aerovate Therapeutics Ocugen Monte Rosa Therapeutics Atea Pharmaceuticals Prime Medicine Alpha Teknova Rocket Pharmaceuticals Lifecore Biomedical ESSA Pharma (NASDAQ:EPIX) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership. Does the media refer more to EPIX or AARD? In the previous week, Aardvark Therapeutics had 10 more articles in the media than ESSA Pharma. MarketBeat recorded 10 mentions for Aardvark Therapeutics and 0 mentions for ESSA Pharma. ESSA Pharma's average media sentiment score of 1.89 beat Aardvark Therapeutics' score of 0.79 indicating that ESSA Pharma is being referred to more favorably in the media. Company Overall Sentiment ESSA Pharma Very Positive Aardvark Therapeutics Positive Do analysts prefer EPIX or AARD? ESSA Pharma currently has a consensus target price of $2.00, suggesting a potential upside of 16.69%. Aardvark Therapeutics has a consensus target price of $33.00, suggesting a potential upside of 141.76%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aardvark Therapeutics is more favorable than ESSA Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ESSA Pharma 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is EPIX or AARD more profitable? Aardvark Therapeutics' return on equity of 0.00% beat ESSA Pharma's return on equity.Company Net Margins Return on Equity Return on Assets ESSA PharmaN/A -23.48% -22.86% Aardvark Therapeutics N/A N/A N/A Do insiders & institutionals hold more shares of EPIX or AARD? 75.1% of ESSA Pharma shares are held by institutional investors. 15.5% of ESSA Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better earnings and valuation, EPIX or AARD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioESSA PharmaN/AN/A-$28.54M-$0.63-2.72Aardvark TherapeuticsN/AN/A-$20.59MN/AN/A SummaryAardvark Therapeutics beats ESSA Pharma on 7 of the 10 factors compared between the two stocks. Get ESSA Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPIX vs. The Competition Export to ExcelMetricESSA PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$76.08M$2.43B$5.50B$9.00BDividend YieldN/A1.77%5.39%4.10%P/E Ratio-2.728.8826.5720.02Price / SalesN/A672.33415.46120.95Price / CashN/A151.5836.1356.90Price / Book0.614.618.065.50Net Income-$28.54M$31.16M$3.15B$248.50M7 Day Performance-1.49%0.51%1.72%2.61%1 Month Performance0.23%7.63%3.92%5.42%1 Year Performance-64.51%1.44%35.02%20.76% ESSA Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPIXESSA Pharma1.9912 of 5 stars$1.71+0.8%$2.00+16.7%-65.5%$76.08MN/A-2.7250AARDAardvark TherapeuticsN/A$13.33+19.8%$31.25+134.4%N/A$289.26MN/A0.0018News CoverageAnalyst ForecastAnalyst RevisionGap DownOLMAOlema Pharmaceuticals2.5162 of 5 stars$4.19+1.5%$24.50+484.7%-56.4%$286.68MN/A-2.0870News CoveragePositive NewsAVTEAerovate TherapeuticsN/A$9.89+5.1%N/A-82.4%$286.66MN/A-3.3120Gap DownHigh Trading VolumeOCGNOcugen1.3436 of 5 stars$0.98-7.4%$6.00+511.6%-42.5%$286.51M$4.52M-5.1680High Trading VolumeGLUEMonte Rosa Therapeutics1.8118 of 5 stars$4.64+0.2%$15.50+234.1%+31.8%$285.41M$75.62M58.0190Positive NewsAVIRAtea Pharmaceuticals3.1341 of 5 stars$3.32+2.2%$6.00+80.7%+12.4%$284.13MN/A-2.0170News CoveragePositive NewsPRMEPrime Medicine3.5854 of 5 stars$2.16+4.3%$10.08+366.8%-41.9%$283.60M$3.85M-1.05234High Trading VolumeTKNOAlpha Teknova3.0395 of 5 stars$5.28-5.0%$8.50+61.0%+313.8%$282.16M$37.74M-11.00240News CoveragePositive NewsRCKTRocket Pharmaceuticals4.8897 of 5 stars$2.63-2.6%$18.60+607.2%-85.4%$280.86MN/A-1.00240LFCRLifecore Biomedical1.6188 of 5 stars$7.39+6.5%$8.00+8.3%+70.3%$273.65M$128.26M-5.10690Positive News Related Companies and Tools Related Companies Aardvark Therapeutics Alternatives Olema Pharmaceuticals Alternatives Aerovate Therapeutics Alternatives Ocugen Alternatives Monte Rosa Therapeutics Alternatives Atea Pharmaceuticals Alternatives Prime Medicine Alternatives Alpha Teknova Alternatives Rocket Pharmaceuticals Alternatives Lifecore Biomedical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EPIX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.......Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ESSA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
